United States Capecitabine Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The Capecitabine Market is expected to reach at a high CAGR during the forecast period (2024-2031).

Key Development:

Japan: Recent Industry Developments

✅ In August 2025, Daiichi Sankyo's ENHERTU® (trastuzumab deruxtecan) received approval in Japan for the treatment of adult patients with hormone receptor-positive, HER2-low or HER2-ultralow unresectable or recurrent breast cancer, broadening the eligible patient population.

✅ In March 2025, Daiichi Sankyo launched DATROWAY® (datopotamab deruxtecan) in Japan as the first TROP2-directed therapy for patients with previously treated unresectable or recurrent HR-positive, HER2-negative breast cancer.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/capecitabine-market?sb

Recent Mergers and acquisitions:

United States: Recent M&A Developments

✅ In July 2025, Sanofi completed the acquisition of Blueprint Medicines for $9.5 billion, strengthening its oncology portfolio and potentially influencing future Capecitabine combination therapies.

✅ In April 2025, Johnson & Johnson finalized its $14.6 billion acquisition of Intra-Cellular Therapies, enhancing its oncology pipeline, including treatments relevant to Capecitabine-based regimens.

✅ In February 2021, Dr. Reddy's Laboratories launched a generic version of Xeloda (capecitabine) tablets in the United States market, expanding access to this essential chemotherapy agent.

Japan: Recent M&A Developments

✅ In August 2025, Daiichi Sankyo's ENHERTU® (trastuzumab deruxtecan) received approval in Japan for the treatment of adult patients with hormone receptor-positive, HER2-low or HER2-ultralow unresectable or recurrent breast cancer, broadening the eligible patient population and influencing Capecitabine usage.

Key Players:

=> F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd, Shilpa Medicare limited, Atom Pharma, Global Calcium, LGM Pharma, Cipla Ltd, Teva Pharmaceuticals, Angel Biogenics Pvt Ltd, Salvavidas Pharma and among others.

Growth Forecast Projected:

The Global Capecitabine Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Capecitabine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=capecitabine-market

Key Segments:

➥ By Indication: Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Others

➥ By Synthesis Type: Chemical-based API, Biological API, Highly Potent API (HPAPI)

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Capecitabine Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Capecitabine producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Capecitabine revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/capecitabine-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.